CLNN Clene Inc.

Price Chart

Executive Summary

Clene reported Q1 2026 results with total revenue of $15K (down 81% YoY from $81K) and a net loss of $8.1M ($0.69/share) vs a loss of $0.8M ($0.09/share) in Q1 2025. The wider loss was driven by $4.6M in one-time equity issuance costs and $1.1M in warrant liability fair value changes from the January 2026 financing. Operationally, the company highlighted a successful FDA Type C meeting supporting a planned NDA submission for CNM-Au8 in ALS in Q3 2026, and amended its convertible debt facility to extend maturity to August 2027 with no principal/interest payments before then. The company also completed a $7M registered direct offering in May 2026. Cash of $5.9M at quarter-end, plus the May proceeds and debt amendment, is expected to fund operations into Q4 2026.

Actionable Insight

Key Facts

• Total revenue fell 81% YoY to $15K (product revenue $1K, royalty $14K)
• Net loss widened to $8.1M ($0.69/share) from $0.8M ($0.09/share) in Q1 2025
• Operating loss improved to $2.1M from $4.1M YoY on lower R&D and G&A spend
• Cash and cash equivalents $5.9M at March 31, 2026 vs $5.2M at Dec 31, 2025
• Completed $7M registered direct offering in May 2026
• Amended $10M convertible debt facility: maturity extended to Aug 2027, no principal/interest payments before maturity
• FDA Type C meeting confirmed biomarker data may support NDA submission under accelerated approval pathway
• NDA submission for CNM-Au8 in ALS planned for Q3 2026; confirmatory Phase 3 trial (RESTORE-ALS) planned for Q1 2027
• Cash runway extended into Q4 2026 with May proceeds and debt amendment; potential $7M warrant exercises tied to NDA acceptance could extend into 2027

Financial Impact

Net loss of $8.1M in Q1 2026 vs $0.8M in Q1 2025, driven by $4.6M loss on initial equity issuance and $1.1M warrant liability fair value changes

Risk Factors

• NDA submission and FDA acceptance are binary events — rejection or complete response letter would be devastating for a pre-revenue company with $5.9M cash
• Substantial dilution from recent offerings (shares outstanding grew from 10.8M at Dec 2025 to 11.8M at Mar 2026, plus May 2026 offering)
• Stockholders' deficit of $18.8M and accumulated deficit of $316.4M indicate ongoing solvency risk
• Warrant and derivative liabilities of $14.4M create potential for further dilution or cash demands
• Historical performance shows high volatility — prior bullish calls on this ticker have produced mixed results

Market Snapshot

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status